AstraZeneca Modifies ARMS License to BTG and DxS; New Deal Enables Shops to Outlicense Tech | GenomeWeb

NEW YORK, Jan. 9 (GenomeWeb News) - AstraZeneca modified its agreement with BTG and DxS over licenses for the Amplification Refractory Mutation System, the companies said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.